- Home
- QNRX vs CMMB Comparison
QNRX vs CMMB Comparison
Compare QNRX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNRX | CMMB |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 11.2M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | QNRX | CMMB |
|---|---|---|
| Price | $4.90 | $2.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 23.1K | ★ 41.4K |
| Earning Date | 05-07-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $46.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $0.87 |
| 52 Week High | $41.80 | $3.86 |
Technical Indicators
Market Signals| Indicator | QNRX | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 29.59 | 66.56 |
| Support Level | N/A | $1.44 |
| Resistance Level | $6.84 | $2.24 |
| Average True Range (ATR) | 0.43 | 0.15 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 8.57 | 83.50 |
Price Performance
Historical ComparisonAbout QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.